Valion Bio, Inc.
VBIO
$2.40
-$0.10-4.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 15.87% | -38.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 15.87% | -38.57% |
| Cost of Revenue | -- | -- | -- | 254.88% | -- |
| Gross Profit | -- | -- | -- | -429.55% | -- |
| SG&A Expenses | 263.64% | 262.76% | 542.75% | 40.55% | 2.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 282.84% | 309.15% | 833.11% | 68.85% | 19.35% |
| Operating Income | -282.84% | -309.15% | -691.95% | -73.52% | -32.54% |
| Income Before Tax | -321.31% | -353.39% | -704.45% | -81.41% | -32.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -321.31% | -353.39% | -704.45% | -81.41% | -32.31% |
| Earnings from Discontinued Operations | 82.03% | 117.83% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -267.84% | -312.92% | -92.89% | -81.41% | -52.53% |
| EBIT | -282.84% | -309.15% | -691.95% | -73.52% | -32.54% |
| EBITDA | -261.72% | -309.16% | -690.94% | -73.64% | -32.57% |
| EPS Basic | 0.82% | 11.42% | 63.33% | 49.09% | -- |
| Normalized Basic EPS | -9.85% | 6.29% | -- | 52.23% | -- |
| EPS Diluted | 0.82% | 11.42% | 63.33% | 49.09% | -- |
| Normalized Diluted EPS | -9.85% | 6.29% | -- | 52.23% | -- |
| Average Basic Shares Outstanding | 283.00% | 383.84% | 301.74% | 261.64% | -- |
| Average Diluted Shares Outstanding | 283.00% | 383.84% | 301.74% | 261.64% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |